Pharmaceutical composition for preventing or treating wound, comprising indirubin derivative as active ingredient

Abstract

The present disclosure relates to a composition for preventing or treating wound. The composition according to the present disclosure contains, as an active ingredient, an indirubin derivative alone or one or more selected from a group consisting of an indirubin derivative, an Euodia sutchuenensis Dode extract, methyl vanillate, hesperidin and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring not only in a normal state but also in a diabetic state. Furthermore, since the composition exhibits excellent effects in healing diabetic wound as well as general wound, it can be usefully used as a pharmaceutical composition, cosmetic composition or food composition for alleviating, preventing or treating general wound or diabetic wound, or as a veterinary composition for treating diabetic wound.

1 . A pharmaceutical composition for preventing or treating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the composition further comprises an  Euodia sutchuenensis  Dode extract. 
     
     
         3 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the composition further comprises one or more selected from a group consisting of methyl vanillate, hesperidin and quercitrin. 
     
     
         4 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the wound is caused by burn, ulcer, injury, surgical operation, childbirth, chronic wound, diabetic wound or dermatitis. 
     
     
         5 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the pharmaceutical composition is for topical application to skin. 
     
     
         6 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the pharmaceutical composition is prepared into a formulation selected from a group consisting of a cream, a gel, an ointment, an emulsion, a suspension, a spray and a transdermal patch. 
     
     
         7 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the pharmaceutical composition is an emulsion formulation further comprising an oil, a surfactant and a polyethylene glycol. 
     
     
         8 . The pharmaceutical composition for preventing or treating wound according to  claim 7 , wherein a mixing weight ratio of the oil, the surfactant and the polyethylene glycol is 0.3-30:1:2-2.5. 
     
     
         9 . The pharmaceutical composition for preventing or treating wound according to  claim 1 , wherein the active ingredient is comprised in an amount of 1-20 wt % based on the total weight of the composition. 
     
     
         10 . The pharmaceutical composition for preventing or treating wound according to  claim 7 , wherein the surfactant is one or more selected from a group consisting of polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan monopalmitate (Tween 40), polyoxyethylene sorbitan monostearate (Tween 60) and polyoxyethylene sorbitan oleate (Tween 80). 
     
     
         11 . The pharmaceutical composition for preventing or treating wound according to  claim 7 , wherein the oil is one or more selected from a group consisting of polyethoxylated castor oil (Kolliphor® EL), sunflower oil and olive oil. 
     
     
         12 . The pharmaceutical composition for preventing or treating wound according to  claim 7 , wherein the composition further comprises a cyclodextrin and the cyclodextrin is comprised in an amount of 100-1000 parts by weight based on 100 parts by weight of the active ingredient present in the composition. 
     
     
         13 . The pharmaceutical composition for preventing or treating wound according to  claim 7 , wherein the emulsion formulation is a stable formulation not exhibiting change in Wnt activity and solubility in distilled water at 4-25° C. for 3 months. 
     
     
         14 . A pharmaceutical composition for a non-human animal for treating or alleviating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient: 
       
         
           
           
               
               
           
         
       
     
     
         15 . A cosmetic composition for preventing or alleviating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient: 
       
         
           
           
               
               
           
         
       
     
     
         16 . The cosmetic composition for preventing or alleviating wound according to  claim 15 , wherein the composition further comprises an  Euodia sutchuenensis  Dode extract. 
     
     
         17 . The cosmetic composition for preventing or alleviating wound according to  claim 15 , wherein the composition further comprises one or more selected from a group consisting of methyl vanillate, hesperidin and quercitrin. 
     
     
         18 . The cosmetic composition for preventing or alleviating wound according to  claim 15 , wherein the cosmetic composition is an emulsion formulation further comprising an oil, a surfactant and a polyethylene glycol. 
     
     
         19 . The cosmetic composition for preventing or alleviating wound according to  claim 15 , wherein a mixing weight ratio of the oil, the surfactant and the polyethylene glycol is 0.3-30:1:2-2.5. 
     
     
         20 . The cosmetic composition for preventing or alleviating wound according to  claim 15 , wherein the active ingredient is comprised in an amount of 1-20 wt % based on the total weight of the composition. 
     
     
         21 . The cosmetic composition for preventing or alleviating wound according to  claim 18 , wherein the surfactant is one or more selected from a group consisting of polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan monopalmitate (Tween 40), polyoxyethylene sorbitan monostearate (Tween 60) and polyoxyethylene sorbitan oleate (Tween 80). 
     
     
         22 . The cosmetic composition for preventing or alleviating wound according to  claim 18 , wherein the oil is one or more selected from a group consisting of polyethoxylated castor oil (Kolliphor® EL), sunflower oil and olive oil. 
     
     
         23 . The cosmetic composition for preventing or alleviating wound according to  claim 18 , wherein the composition further comprises a cyclodextrin and the cyclodextrin is comprised in an amount of 100-1000 parts by weight based on 100 parts by weight of the active ingredient present in the composition. 
     
     
         24 . A food composition for preventing or alleviating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient: 
       
         
           
           
               
               
           
         
       
     
     
         25 . The food composition for preventing or alleviating wound according to  claim 24 , wherein the composition further comprises an  Euodia sutchuenensis  Dode extract. 
     
     
         26 . The food composition for preventing or alleviating wound according to  claim 24 , wherein the composition further comprises one or more selected from a group consisting of methyl vanillate, hesperidin and quercitrin.